ArticleFrontiers in oncology2026
Preoperative CT-derived liver fat fraction and visceral adipose tissue index enhance postoperative recurrence risk stratification in colorectal cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative recurrence remains a major cause of treatment failure in colorectal cancer (CRC). We evaluated whether preoperative computed tomography (CT)-derived liver fat fraction (LFF) and visceral adipose tissue index (VATI) improve postoperative recurrence-risk prediction. Methods: This multi-cohort study included 525 patients after curative-intent surgery: a training cohort (n=260), external validation cohort (n=208), and exploratory prospective cohort (n=57). Candidate clinicopathologic and CT-derived variables were evaluated using Cox regression. Performance was assessed with Harrell C-index, time-dependent area under the receiver operating characteristic curve (AUC) at 12 and 24 months, calibration, decision curve analysis, and Kaplan-Meier analysis. Results: RFS events were observed in 129 patients. The final model included five predictors. N1-2 stage (hazard ratio [HR], 3.332; 95% confidence interval [CI], 1.807-6.145), elevated carbohydrate antigen 19-9 (CA19-9; HR, 2.414; 95% CI, 1.459-3.994), lymphovascular invasion (HR, 2.166; 95% CI, 1.250-3.752), VATI per 1-standard-deviation increase (HR, 1.519; 95% CI, 1.217-1.896), and LFF per 1-standard-deviation increase (HR, 2.228; 95% CI, 1.728-2.871) were independently associated with recurrence-free survival. C-indices were 0.851, 0.809, and 0.828 in the training, external, and prospective cohorts, respectively. Prospective 12- and 24-month AUCs were 0.759 (95% CI, 0.242-1.000) and 0.890 (95% CI, 0.709-1.000), with the latter based on only 20 evaluable patients. The combined validation cohort yielded a C-index of 0.813 and 12- and 24-month AUCs of 0.807 and 0.860. Conclusion: CT-derived VATI and LFF improved risk stratification beyond routine clinicopathologic variables. The prospective findings remain exploratory and require confirmation in larger cohorts before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.